HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sabiporide improves cardiovascular function and attenuates organ injury from severe sepsis.

AbstractBACKGROUND:
The aim of the present study was to evaluate the efficacy of orally administered sabiporide, a selective Na(+)/H(+) exchanger inhibitor on whole body protection from severe sepsis in rats.
METHODS:
Series 1: Sepsis was induced by cecal ligation and puncture (CLP). Animals received treatment of vehicle or sabiporide (10 mg/kg, p.o.). The experiment was terminated 20 h after CLP. Series 2: At 20 h after CLP, the necrotic cecum was excised and the abdominal cavity was washed. The animals were then returned to their cages. The experiment was terminated 7 d after CLP.
RESULTS:
Series 1: Compared with vehicle treatment, administration of sabiporide prevented hemodynamic derangement and improved cardiac function as evidenced by improved arterial pressure, left ventricle systolic pressure, ±dp/dt max, ejection fraction and fractional shorting, attenuated left ventricle end-diastolic pressure elevation, and wall motion abnormality. Furthermore, administration of sabiporide attenuated intestinal mucosal hyperpermeability and reduced accumulation of abdominal ascites. In addition, treatment with sabiporide also reduced plasma levels of tumor necrosis factor-α, interleukin 6, interleukin 10, cardiac troponin, aspartate aminotransferase, alanine aminotransferase, urea, and lactate, and attenuated neutrophil infiltration in the liver and gut. Series 2: Administration of sabiporide improved the 7-day survival rate after CLP in rats (42% in vehicle group versus 75% in sabiporide group).
CONCLUSIONS:
Administration of sabiporide improved cardiovascular performance, lessened the inflammatory response, tissue hypoperfusion and multiorgan injury, and most importantly reduced mortality.
AuthorsXinchun Lin, Dongwon Lee, Dongmei Wu
JournalThe Journal of surgical research (J Surg Res) Vol. 188 Issue 1 Pg. 231-7 (May 01 2014) ISSN: 1095-8673 [Electronic] United States
PMID24411641 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2014 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers
  • Guanidines
  • Sodium-Hydrogen Exchangers
  • sabiporide
Topics
  • Animals
  • Ascites (prevention & control)
  • Biomarkers (blood)
  • Cardiovascular Diseases (etiology, prevention & control)
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Guanidines (pharmacology, therapeutic use)
  • Heart (drug effects)
  • Hemodynamics (drug effects)
  • Intestinal Mucosa (drug effects, metabolism)
  • Male
  • Multiple Organ Failure (prevention & control)
  • Permeability (drug effects)
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Sepsis (blood, complications, drug therapy)
  • Sodium-Hydrogen Exchangers (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: